-
公开(公告)号:KR1020120030391A
公开(公告)日:2012-03-28
申请号:KR1020117028233
申请日:2010-05-27
Applicant: 전남대학교산학협력단
IPC: A61K48/00 , C07K14/255 , A01K67/027 , A61K35/00
CPC classification number: A01K67/027 , A01K2207/12 , A01K2227/105 , A01K2267/0375 , A61K48/0033 , A61K2035/11 , C07K14/255 , C12N2830/001
Abstract: PURPOSE: A selective infart-tissue-targeting bacteria and use thereof are provided to improve affinity and specificity to infarction myocardium or infarction brain, thereby reducing transfection other than heart. CONSTITUTION: A drug delivery system for infarcted tissues includes obligatory anaerobic or facultative anaerobic bacteria. The bactia are Salmonella, Clostridium, Bifidobacterium, E. coli, Yersinia enterocohtica, Listeria monocytogenies, Mycoplasma hominis, or Streptococcus. The bacteria are mutants which are deficient in ppGpp synthesis function. The bacteria comprise ppGpp for ppGpp synthesis, inactivated relA gene which codes synthetase or spoT gene. The infarction indicates either myocardial infarction or cerebral infarction. A pharmaceutical composition for treating the infarction comprises effective dose of drug delivery system and a pharmaceutically allowed carrier. The drug carrier includes the infarction treatment drug.
Abstract translation: 目的:提供选择性的infart组织靶向细菌及其用途,以改善对梗塞心肌或梗死脑的亲和力和特异性,从而减少心脏以外的转染。 构成:用于梗塞组织的药物递送系统包括必需的厌氧或兼性厌氧细菌。 细菌是沙门氏菌属,梭菌属,双歧杆菌属,大肠杆菌,肠易耶一肠炎,单核细胞增多性李斯特菌,人支原体或链球菌。 细菌是缺乏ppGpp合成功能的突变体。 细菌包含ppGpp用于ppGpp合成,灭活的relA基因编码合成酶或spoT基因。 梗死表示心肌梗塞或脑梗塞。 用于治疗梗死的药物组合物包括有效剂量的药物递送系统和药学上允许的载体。 药物载体包括梗死治疗药物。
-
公开(公告)号:KR100661482B1
公开(公告)日:2006-12-27
申请号:KR1020060030086
申请日:2006-04-03
Applicant: 전남대학교산학협력단
IPC: G02F1/167
Abstract: An electrophoresis apparatus having collecting grooves for refining DNA is provided to collect DNA moving according to an electric field in a collecting groove to directly acquire the DNA. An electrophoresis apparatus includes a tank(110), a gel(130), a groove forming device, and a power supply(120). The tank is filled with a buffer solution. The gel is placed inside the tank and has an injection hole(130a) through which samples are injected and a collecting groove(130b) for collecting samples moved from the injection hole. The groove forming device forms the injection hole and the collecting groove in the gel. The power supply supplies power to the tank. The groove forming device includes an injection hole forming unit for forming the injection hole and a collecting groove forming unit for forming the collecting groove. The distance between the injection hole forming unit and the collecting groove forming unit is variable.
Abstract translation: 提供具有用于精制DNA的收集槽的电泳装置,以收集根据收集槽中的电场移动的DNA以直接获取DNA。 电泳装置包括槽(110),凝胶(130),槽形成装置和电源(120)。 该罐充满缓冲溶液。 凝胶被放置在罐内并具有注射样品的注射孔(130a)和用于收集从注射孔移动的样品的收集槽(130b)。 槽形成装置在凝胶中形成注入孔和收集槽。 电源为油箱供电。 该槽形成装置包括用于形成注入孔的注入孔形成单元和用于形成收集槽的收集槽形成单元。 注入孔形成单元和收集槽形成单元之间的距离是可变的。
-
公开(公告)号:KR1020170125198A
公开(公告)日:2017-11-14
申请号:KR1020160055088
申请日:2016-05-04
Applicant: 전남대학교산학협력단 , 전남대학교병원
Abstract: 본발명은뇌-혈관문맥손상진단용마커에관한것으로서, Cav-1 유전자로부터발현되는 mRNA 및단백질로이루어진군에서선택된적어도하나를포함하는뇌-혈관문맥손상진단용마커; Cav-1 유전자로부터발현되는 mRNA 및단백질로이루어진군에서선택된적어도하나를검출하기위한시약을포함하는뇌-혈관문맥손상진단용키트; 검체의 Cav-1 mRNA 또는단백질발현수준을측정하는단계를포함하는, 뇌-혈관문맥손상여부판단을위한정보제공방법; 및 Cav-1 단백질을포함하는뇌-혈관문맥손상치료용조성물로써, 뇌-혈관문맥손상을조기발견, 치료할수 있고, 뇌-혈관문맥손상으로인한질병을치료할수 있으며, 검체로혈액등을이용하므로검체의채취가용이하고, 환자에게위해가없으며, 진단결과를보다시술전 신속히알 수있는장점이있는뇌-혈관문맥손상진단용마커및 그를이용한진단키트와뇌-혈관문맥손상치료용조성물에관한것이다.
Abstract translation: 本发明涉及用于诊断脑血管门静脉病变的标志物,其包含选自由Cav-1基因表达的mRNA和蛋白质组成的组中的至少一种标志物, 一种用于诊断脑血管门脉损伤的试剂盒,其包含用于检测选自Cav-1基因表达的mRNA和蛋白质中的至少一种的试剂; 测量样品的Cav-1 mRNA或蛋白质表达水平; 和大脑,包括CAV-1蛋白使用,可以治疗由血管方面的损害,血液样本等疾病 - 如血管方面损伤治疗的组合物,早期脑找到矿脉方面的伤害,并且你可以把大脑 因为采样的容易,也没有为了病人,不是程序的诊断结果之前快速的好处可以看出脑血管方面损伤的诊断标志物,以及诊断试剂盒和脑与他 - 龙的血管方面损伤的治疗成分 会的。
-
14.
公开(公告)号:KR1020170107876A
公开(公告)日:2017-09-26
申请号:KR1020160121291
申请日:2016-09-22
Applicant: 전남대학교산학협력단 , 전남대학교병원 , 대한민국(농촌진흥청장)
IPC: A61K36/899 , A61K31/196 , A61K9/46 , A61K9/20 , A61K9/48 , A61K45/06
CPC classification number: A61K36/899 , A61K9/0007 , A61K9/20 , A61K9/48 , A61K31/196 , A61K45/06 , A61K2300/00
Abstract: 본발명은귀리추출물을유효성분으로포함하는난청의예방또는치료용조성물에관한것이다. 보다구체적으로, 본발명은귀리추출물로서아베난쓰라마이드또는이의유도체를유효성분으로포함하는난청의예방또는치료용조성물에관한것이다.
Abstract translation: 本发明涉及用于预防或治疗听力损失的组合物,其包含燕麦提取物作为活性成分。 更具体而言,本发明涉及一种用于预防或治疗听力损失的组合物,其包含作为燕麦提取物的作为活性成分的桂皮甙或其衍生物。
-
公开(公告)号:KR101733085B1
公开(公告)日:2017-05-08
申请号:KR1020160066932
申请日:2016-05-31
Applicant: 전남대학교산학협력단 , 대한민국(농촌진흥청장)
IPC: A61K31/196 , A61K36/899 , A23L1/30
Abstract: 본발명은귀리추출물을유효성분으로포함하는퇴행성신경질환의예방또는치료용약제학적조성물및 건강기능식품에관한것이다. 보다구체적으로, 본발명은귀리추출물로서아베난쓰라마이드 C(Avenanthramide C) 또는이의유도체, 예를들면에베난쓰라마이드 C 메틸에스터를유효성분으로포함하는알츠하이머질병의예방또는치료용약제학적조성물및 건강기능식품에관한것이다.
-
公开(公告)号:KR101819658B1
公开(公告)日:2018-01-17
申请号:KR1020160106088
申请日:2016-08-22
Applicant: 전남대학교산학협력단 , 대한민국(농촌진흥청장)
IPC: A61K31/196 , A61K36/899 , A23L1/30
Abstract: 본발명은귀리추출물을유효성분으로포함하는퇴행성신경질환의예방또는치료용약제학적조성물및 건강기능식품에관한것이다. 보다구체적으로, 본발명은귀리추출물로서아베난쓰라마이드 C(Avenanthramide C) 또는이의유도체, 예를들면에베난쓰라마이드 C 메틸에스터를유효성분으로포함하는알츠하이머질병의예방또는치료용약제학적조성물및 건강기능식품에관한것이다.
-
-
-
-
-